ACTO’s Post

At AnalyticsIQ, we understand the importance of personalized marketing communications and engagement when it comes to patients in healthcare. But what about healthcare providers? Recognizing and understanding the provider-as-a-person can greatly improve the way organizations engage with HCPs and empower them to do their best work.   By linking NPI data with consumer insights, organizations serving providers are able to unlock a new dimension in healthcare marketing in order to foster stronger connections with HCPs and potentially enable them to enhance patient care.   Our own resident healthcare expert, Christine (Boley) Lee, shared her thoughts on this innovative approach to HCP engagement with Pharmaceutical Executive.   Interested in learning more? Check out the article here: #HealthcareEngagement #NPI #HCPs

3 Ways Biopharmas Are Using Field Insights to Better Engage HCPs According to Digital Health Coalition data, only 27% of HCPs say that biopharmas communicate with them in a personalized and relevant way. The latest Veeva Systems Pulse Field Trends Report, a quarterly industry benchmark report analyzing the activity of more than 80% of biopharma field teams worldwide and 600 million HCP interactions, reviews previously published insights into HCP engagement. Learn how three biopharma field teams are turning these insights into action. Download Report Now: https://lnkd.in/e6_Re3CQ

Ever felt like your biopharma field team's HCP interactions are missing the mark? You’re not alone! According to the Digital Health Coalition, only 27% of HCPs feel that biopharmas are communicating with them in a relevant and personalised way. So, if you’re curious about how industry leaders are effectively engaging with HCPs, dive into the Veeva Systems Pulse Field Trends in the report below! 🚀📈

📈 "Measuring Impact: A Key Challenge for Pharma" provides actionable advice on leveraging data and measuring the impact of HCP engagement. Discover the insights in our report, "Measuring Impact." Download it today at https://bit.ly/3ulBQYQ! #MeasuringImpact #DataAnalytics 📊

📈 "Measuring Impact: A Key Challenge for Pharma" provides actionable advice on leveraging data and measuring the impact of HCP engagement. Discover the insights in our report, "Measuring Impact." Download it today at https://bit.ly/3ulBQYQ! #MeasuringImpact #DataAnalytics 📊

Unveiling Pharma's Vision 2024: Navigating Shifts in HCP Engagement with Precision. A recent game-changing study, "The Future of HCP Engagement Impact," by EPG Health, has illuminated the industry's evolving priorities and challenges in the dynamic realm of digital engagement and medical affairs. 🔍 57% of pharmaceutical companies are placing 'HCP insight (needs and behavior)' at the forefront of their strategic HCP engagement priorities for the upcoming year. This marks a considerable departure from the landscape of 2021-2, where the emphasis was on cultivating a 'digital culture or mindset.' 🌐 MSLs Take Center Stage: For the first time in industry history, the study unveils a seismic shift: MSLs have surpassed the sales force as the most critical channel for delivering scientific information to HCPs. A staggering 84% view MSL activities as critical or very important, outpacing the traditional sales force at 77%. 💡 Addressing Gaps: While brand information remains a top priority, the study reveals a nuanced approach as 27% anticipate increased budgets for disease awareness, aligning with HCPs' escalating demand for focused content. This dual strategy highlights a strategic pivot in acknowledging and catering to diverse HCP needs. 📱 Social Media Discrepancy: While 41% of HCPs express a growing demand for content via social media, pharma has curiously reduced its emphasis on social channels over the past two years. This discrepancy highlights a potential gap between industry practices and the evolving preferences of a younger demographic, with figures soaring to 64% among those under 34. A potential hurdle could be local SOP and compliance challenges. 📊 Measuring Impact: The study reveals that 'demonstrating behavioural impact and outcomes' is the second most pressing challenge for pharma's digital HCP engagement, with a significant 63% describing it as a major obstacle. This underscores a persistent struggle in measuring the true effectiveness of industry efforts beyond traditional reach metrics. The compelling figures from the EPG Health study serve as a powerful call to action, urging the industry to recalibrate its approach, leverage emerging channels, and establish robust measurement strategies to illuminate the true impact of medical-led activities. It's not just a new year; it's a pivotal era in pharmaceutical HCP engagement, where precision and adaptation will be the keys to success. #Pharma2024 #HCPInsights #DigitalTransformation 🚀

📈 "Measuring Impact: A Key Challenge for Pharma" provides actionable advice on leveraging data and measuring the impact of HCP engagement. Discover the insights in our report, "Measuring Impact." Download it today at https://bit.ly/3ulBQYQ! #MeasuringImpact #DataAnalytics 📊

❓𝗗𝗼𝗲𝘀 𝗬𝗼𝘂𝗿 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝗧𝗲𝗮𝗺 𝗡𝗲𝗲𝗱 𝗮 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗔𝗿𝗲𝗮 𝗥𝗲𝘃𝗶𝗲𝘄❓🌿 𝘕𝘦𝘦𝘥 𝘺𝘰𝘶𝘳 𝘵𝘦𝘢𝘮 𝘢𝘭𝘪𝘨𝘯𝘦𝘥 𝘰𝘯 𝘺𝘰𝘶𝘳 𝘱𝘳𝘰𝘥𝘶𝘤𝘵? 𝘈 𝘥𝘪𝘴𝘦𝘢𝘴𝘦 𝘢𝘳𝘦𝘢 𝘳𝘦𝘷𝘪𝘦𝘸 𝘤𝘢𝘯 𝘮𝘢𝘬𝘦 𝘵𝘩𝘢𝘵 𝘩𝘢𝘱𝘱𝘦𝘯. While awaiting clinical trial results, teams prepare for regulatory compliance, stakeholder support, and market entry, all while building internal support. This is where a Disease Area Review (DAR) can help. 𝗔 𝗗𝗔𝗥 𝗶𝘀 𝗮 𝗰𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗼𝗳 𝗮 𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗰𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻 𝗼𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗮𝗿𝗲𝗮. A DAR can help with: • 𝗨𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲: Gain in-depth insights into the current market, including existing treatments, key players, and market trends. Identify opportunities and threats in the market.    • 𝗖𝗹𝗮𝗿𝗶𝗳𝘆𝗶𝗻𝗴 𝗨𝗻𝗺𝗲𝘁 𝗡𝗲𝗲𝗱𝘀: Analyze the current treatment landscape and patient outcomes to highlight gaps in existing therapies and unmet medical needs. This information is also crucial for developing value propositions for new products.    • 𝗦𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲-𝗕𝗮𝘀𝗲𝗱 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀: The comprehensive data and insights from a DAR support evidence-based decision-making in developing market access strategies, pricing, and reimbursement plans.    • 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗮𝗻𝗱 𝗣𝗼𝗹𝗶𝗰𝘆 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀: Navigate approval processes and align with policy requirements.    • 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗣𝗹𝗮𝗻𝗻𝗶𝗻𝗴: Provide a clear picture of the competitive landscape, potential market size, and growth opportunities, to position your new product effectively in the market.    • 𝗦𝘁𝗮𝗸𝗲𝗵𝗼𝗹𝗱𝗲𝗿 𝗘𝗻𝗴𝗮𝗴𝗲𝗺𝗲𝗻𝘁: Craft targeted communication strategies for engaging with key stakeholders, including healthcare providers, payers, and patient advocacy groups, by providing them with relevant and compelling data. 🔍  𝗗𝗔𝗥𝘀 𝗰𝗮𝗻 𝗽𝗿𝗼𝘃𝗶𝗱𝗲 𝗮 𝘀𝗼𝗹𝗶𝗱 𝗳𝗼𝘂𝗻𝗱𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝗯𝘂𝗶𝗹𝗱 𝗮 𝗴𝗹𝗼𝗯𝗮𝗹 𝘃𝗮𝗹𝘂𝗲 𝗱𝗼𝘀𝘀𝗶𝗲𝗿. 🔍  𝗗𝗔𝗥𝘀 e𝗾𝘂𝗶𝗽 𝗺𝗮𝗿𝗸𝗲𝘁 𝗮𝗰𝗰𝗲𝘀𝘀 𝘁𝗲𝗮𝗺𝘀 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗻𝗲𝗲𝗱𝗲𝗱 𝘁𝗼 𝗺𝗮𝗸𝗲 𝗶𝗻𝗳𝗼𝗿𝗺𝗲𝗱 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀 🔍  𝗗𝗔𝗥𝘀 𝗲𝗻𝗵𝗮𝗻𝗰𝗲 𝘁𝗵𝗲 𝘀𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹 𝗶𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗮𝗱𝗼𝗽𝘁𝗶𝗼𝗻 𝗼𝗳 𝗻𝗲𝘄 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝘀. Contact APPA to develop a tailored disease area review or request a proposal today! https://lnkd.in/egqSHG7k